$VTAK
Catheter Precision, Inc.

2022 Q1 Form 10-Q Financial Statement

#000156459022020432 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $9.000K $1.118M
YoY Change -99.19% -18.63%
Cost Of Revenue $95.00K $1.373M
YoY Change -93.08% -13.32%
Gross Profit -$86.00K -$255.0K
YoY Change -66.27% 21.43%
Gross Profit Margin -955.56% -22.81%
Selling, General & Admin $2.302M $4.114M
YoY Change -44.04% -34.54%
% of Gross Profit
Research & Development $3.115M $2.816M
YoY Change 10.62% 117.45%
% of Gross Profit
Depreciation & Amortization $100.0K $400.0K
YoY Change -75.0% -20.0%
% of Gross Profit
Operating Expenses $5.417M $6.930M
YoY Change -21.83% -8.58%
Operating Profit -$5.503M -$7.185M
YoY Change -23.41% -7.77%
Interest Expense $52.00K
YoY Change 108.0%
% of Operating Profit
Other Income/Expense, Net $8.000K -$51.00K
YoY Change -115.69% -157.3%
Pretax Income -$5.495M -$6.877M
YoY Change -20.1% -10.7%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.495M -$7.236M
YoY Change -24.06% -6.04%
Net Earnings / Revenue -61055.56% -647.23%
Basic Earnings Per Share
Diluted Earnings Per Share -$274.2K -$2.481M
COMMON SHARES
Basic Shares Outstanding 3.259M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.65M $15.95M
YoY Change 10.64% -31.94%
Cash & Equivalents $17.70M $15.95M
Short-Term Investments
Other Short-Term Assets $1.277M $1.555M
YoY Change -17.88% -13.23%
Inventory $1.059M $2.249M
Prepaid Expenses
Receivables $26.00K $160.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $20.01M $19.92M
YoY Change 0.48% -30.57%
LONG-TERM ASSETS
Property, Plant & Equipment $1.658M $5.213M
YoY Change -68.19% -29.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $36.00K $131.0K
YoY Change -72.52% -25.14%
Total Long-Term Assets $3.733M $5.344M
YoY Change -30.15% -29.79%
TOTAL ASSETS
Total Short-Term Assets $20.01M $19.92M
Total Long-Term Assets $3.733M $5.344M
Total Assets $23.75M $25.26M
YoY Change -6.0% -30.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.171M $977.0K
YoY Change 19.86% -27.95%
Accrued Expenses $2.273M $2.551M
YoY Change -10.9% 5.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $674.0K
YoY Change 130.03%
Total Short-Term Liabilities $3.735M $5.979M
YoY Change -37.53% -0.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.326M
YoY Change -100.0% 601.59%
Other Long-Term Liabilities $1.904M $2.812M
YoY Change -32.29% -22.21%
Total Long-Term Liabilities $1.904M $4.138M
YoY Change -53.99% 8.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.735M $5.979M
Total Long-Term Liabilities $1.904M $4.138M
Total Liabilities $5.639M $10.12M
YoY Change -44.26% 2.96%
SHAREHOLDERS EQUITY
Retained Earnings -$183.8M -$160.4M
YoY Change 14.56%
Common Stock $201.9M $175.6M
YoY Change 14.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.11M $15.15M
YoY Change
Total Liabilities & Shareholders Equity $23.75M $25.26M
YoY Change -6.0% -30.41%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$5.495M -$7.236M
YoY Change -24.06% -6.04%
Depreciation, Depletion And Amortization $100.0K $400.0K
YoY Change -75.0% -20.0%
Cash From Operating Activities -$8.600M -$8.078M
YoY Change 6.46% 14.7%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $20.00K
YoY Change -100.0% -28.57%
Acquisitions
YoY Change
Other Investing Activities $0.00 $309.0K
YoY Change -100.0% -97.19%
Cash From Investing Activities $0.00 $289.0K
YoY Change -100.0% -97.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.18M -163.0K
YoY Change -6956.44% 114.47%
NET CHANGE
Cash From Operating Activities -8.600M -8.078M
Cash From Investing Activities 0.000 289.0K
Cash From Financing Activities 11.18M -163.0K
Net Change In Cash 2.607M -7.952M
YoY Change -132.78% -306.38%
FREE CASH FLOW
Cash From Operating Activities -$8.600M -$8.078M
Capital Expenditures $0.00 $20.00K
Free Cash Flow -$8.600M -$8.098M
YoY Change 6.2% 14.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32301000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32301000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7010000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6877000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7010000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
10000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
201865000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
191937000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183767000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178272000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
18108000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13673000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23747000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21044000
CY2022Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-5495000
CY2021Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-6877000
CY2021Q1 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
-359000
CY2021Q1 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
-359000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5495000
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.27
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-2.36
CY2021Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
-0.12
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.48
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20037
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2917
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-5495000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-7236000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
186000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
455000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
165000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1169000
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-36000
CY2021Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
501000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-78000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
73000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
14000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
240000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
83000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-256000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
406000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2822000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2172000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-93000
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-65000
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-87000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8569000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8078000
CY2021Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
309000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
289000
CY2022Q1 rmed Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
12670000
CY2021Q1 rmed Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
300000
CY2022Q1 rmed Payments Of Offering Costs Related To Issuance Of Common Stock And Warrants
PaymentsOfOfferingCostsRelatedToIssuanceOfCommonStockAndWarrants
1519000
CY2021Q1 rmed Payments Of Offering Costs Related To Issuance Of Common Stock And Warrants
PaymentsOfOfferingCostsRelatedToIssuanceOfCommonStockAndWarrants
198000
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
25000
CY2021Q1 rmed Payments On Equipment Financing
PaymentsOnEquipmentFinancing
265000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11176000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-163000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2607000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7952000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15045000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23906000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17652000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15954000
CY2022Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1411000
CY2021Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
37000
CY2021Q1 rmed Receivables From Sale Of Property And Equipment
ReceivablesFromSaleOfPropertyAndEquipment
222000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13673000
CY2022Q1 rmed Common Stock And Warrants Issued During Period Value
CommonStockAndWarrantsIssuedDuringPeriodValue
9740000
CY2022Q1 rmed Exercise Of Warrants
ExerciseOfWarrants
25000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
165000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5495000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
18108000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
21147000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
65000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1169000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7236000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
15145000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183800000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8600000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17700000
CY2022Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
9700000
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2273000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4119000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y9M
CY2022Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.07
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of interim unaudited condensed <span style="color:#000000;">financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”)</span> requires management to make estimates and assumptions that affect the amounts reported in the interim unaudited condensed financial statements and accompanying notes. The amounts reports could differ under different estimates and assumptions. On an ongoing basis, management evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</p>
CY2022Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior period amounts have been reclassified to conform to the current period presentation in order to reflect the Dermatology Business as discontinued operations.</p>
CY2022Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
959000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
100000
CY2021Q1 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
1113000
CY2021Q1 us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
927000
CY2021Q1 rmed Gros Income Loss From Discontinued Operations
GrosIncomeLossFromDiscontinuedOperations
186000
CY2021Q1 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
502000
CY2021Q1 rmed Disposal Group Including Discontinued Operation Operating Income Loss Gross
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLossGross
-316000
CY2021Q1 rmed Disposal Group Including Discontinued Operation Other Income Expense Net
DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet
-43000
CY2021Q1 us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
-359000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
911000
CY2022Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
93000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
70000
CY2022Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5000
CY2022Q1 us-gaap Inventory Net
InventoryNet
1059000
CY2021Q4 us-gaap Inventory Net
InventoryNet
986000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
100000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4572000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4658000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2914000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2849000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1658000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1809000
CY2022Q1 us-gaap Depreciation
Depreciation
100000
CY2021Q1 us-gaap Depreciation
Depreciation
400000
CY2022Q1 rmed Accrued Offering Costs Current
AccruedOfferingCostsCurrent
974000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
419000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2004000
CY2022Q1 rmed Accrued Consulting Fees
AccruedConsultingFees
255000
CY2021Q4 rmed Accrued Consulting Fees
AccruedConsultingFees
273000
CY2022Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
192000
CY2021Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
195000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
104000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1345000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
329000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
302000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
324000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
445000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
459000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
472000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
486000
CY2022Q1 rmed Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
501000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2687000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
492000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2195000
CY2022Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
0
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
56329950
CY2021 rmed Common Stock Capital Shares Weighted Average Exercise Price
CommonStockCapitalSharesWeightedAverageExercisePrice
0.89
CY2020 rmed Common Stock Capital Shares Weighted Average Exercise Price
CommonStockCapitalSharesWeightedAverageExercisePrice
0.89
CY2022Q1 rmed Percentage Of Cash Compensation For Gross Proceeds Raised
PercentageOfCashCompensationForGrossProceedsRaised
0.075
CY2022Q1 rmed Percentage Of Number Of Common Shares Sold To Issue Warrants
PercentageOfNumberOfCommonSharesSoldToIssueWarrants
0.07
CY2022Q1 rmed Placement Agent Warrants Issued
PlacementAgentWarrantsIssued
1700000
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.625
CY2022Q1 rmed Percentage Of Warrants Exercise Price In The Offering
PercentageOfWarrantsExercisePriceInTheOffering
1.25
CY2022Q1 rmed Warrants Expire Period
WarrantsExpirePeriod
P5Y
CY2022Q1 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
300000
CY2022Q1 rmed Fair Value Assumption Expected Volatility Rate
FairValueAssumptionExpectedVolatilityRate
1.099
CY2022Q1 rmed Fair Value Assumption Risk Free Interest Rate
FairValueAssumptionRiskFreeInterestRate
0.0147
CY2022Q1 rmed Fair Value Assumption Expected Dividend Rate
FairValueAssumptionExpectedDividendRate
0
CY2022Q1 rmed Fair Value Assumption Expected Term
FairValueAssumptionExpectedTerm
P2Y6M

Files In Submission

Name View Source Status
0001564590-22-020432-index-headers.html Edgar Link pending
0001564590-22-020432-index.html Edgar Link pending
0001564590-22-020432.txt Edgar Link pending
0001564590-22-020432-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rmed-10q_20220331.htm Edgar Link pending
rmed-10q_20220331_htm.xml Edgar Link completed
rmed-20220331.xsd Edgar Link pending
rmed-20220331_cal.xml Edgar Link unprocessable
rmed-20220331_def.xml Edgar Link unprocessable
rmed-20220331_lab.xml Edgar Link unprocessable
rmed-20220331_pre.xml Edgar Link unprocessable
rmed-ex311_12.htm Edgar Link pending
rmed-ex312_6.htm Edgar Link pending
rmed-ex321_11.htm Edgar Link pending
rmed-ex322_7.htm Edgar Link pending
Show.js Edgar Link pending